BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:UX-DA003 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of UX-DA003\, from ClinicalTrials.gov estima
 tes.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07911670-8723@assetmemo.bio
DTSTAMP:20261121T005824Z
DTSTART;VALUE=DATE:20290331
DTEND;VALUE=DATE:20290401
SUMMARY:UX-DA003: Phase 1 readout est. (NCT07911670)
DESCRIPTION:UX-DA003\, phase 1\, Parkinson's Disease.\nStudy: Exploratory C
 linical Trial of UX-DA003 Injection for the Treatment of Patients With Par
 kinson's Disease\nEstimated primary completion: March 2029. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/ux-da003#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT07911670
URL:https://assetmemo.bio/drug/ux-da003#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07733349-8723@assetmemo.bio
DTSTAMP:20261121T005824Z
DTSTART;VALUE=DATE:20290831
DTEND;VALUE=DATE:20290901
SUMMARY:UX-DA003: Phase 1/2 readout est. (NCT07733349)
DESCRIPTION:UX-DA003\, phase 1/2\, Parkinson's Disease.\nStudy: Phase I/II 
 Clinical Trial of UX-DA003 Injection for the Treatment of Patients With Pa
 rkinson's Disease\nEstimated primary completion: 31 August 2029. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/ux-da003#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT07733349
URL:https://assetmemo.bio/drug/ux-da003#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
